The introduction of the drug in Australia is creating significant interest within the medical community. This novel dual agonist – acting on both GLP-1 and GIP receptors – shows a potentially powerful approach for https://australianpeptidestore.co/bpc-157-10mg-research-peptide-australian-peptide-store/